Vimizim was Biomarin Pharmaceutical’s largest product and service line in fiscal 2025, bringing in $792.05M of $2.84B (28%).
| Product and Service | FY 2013 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vimizim | $663.74M | $701.05M | $739.78M | $792.05M | ||||||||
| Products Excluding Aldurazyme | — | — | — | $544.47M | ||||||||
| Naglazyme | $443.79M | $420.29M | $479.58M | $485.40M | ||||||||
| Products Excluding Product One | — | — | — | — | ||||||||
| Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, & Firdapse | — | — | — | — | ||||||||
| Brineura, Firdapse, Kuvan, Naglazyme, & Vimizim | — | — | — | — | ||||||||
| Voxzogo | $169.13M | $469.88M | $735.09M | — | ||||||||
| Palynziq | $255.03M | $303.92M | $355.05M | $433.31M | ||||||||
| Product Four | — | — | — | — | ||||||||
| Kuvan | $227.58M | $180.77M | $120.90M | $99.53M | ||||||||
| Aldurazyme Net Product Revenues Marketed By Sanofi | — | — | — | — | ||||||||
| Brineura | $154.33M | $161.89M | $169.08M | $186.40M | ||||||||
| Aldurazyme | $128.42M | $131.25M | $183.89M | $208.51M | ||||||||
| Royalty & Other Revenues | $54.01M | $46.69M | $44.47M | $53.49M | ||||||||
| Roctavian | — | $3.49M | $26.07M | $35.64M | ||||||||
| Firdapse | — | — | — | — | ||||||||
| Product | — | — | — | — | ||||||||
| Net Product Revenues | — | — | — | — | ||||||||
| Total | $2.10B | $2.42B | $2.85B | $2.84B |
Biomarin Pharmaceutical brought in $2.84B from its nine product and service lines in fiscal 2025, the year ended December 31, 2025. Biomarin Pharmaceutical regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $2.85B. Vimizim was the largest at $792.05M (27.9%), ahead of Products Excluding Aldurazyme at $544.47M (19.2%) and Naglazyme at $485.40M (17.1%). The other six lines brought in $1.02B combined.
Compared with fiscal 2024, Palynziq grew fastest, up 22.0% to $433.31M, while Kuvan fell the most, down 17.7% to $99.53M.
Biomarin Pharmaceutical began breaking out Roctavian in fiscal 2023, when it brought in $3.49M. Biomarin Pharmaceutical stopped reporting Voxzogo as a separate line after fiscal 2024, when it brought in $735.09M.
Marketed By Company was Biomarin Pharmaceutical’s largest revenue line in fiscal 2025, bringing in $1.10B of $1.31B (84%).
| Contract with Customer, Sales Channel | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Marketed By Company | $771.31M | $924.81M | $1.10B | ||||||
| Marketed By Sanofi | $131.25M | $183.89M | $208.51M | ||||||
| Marketed By Genzyme | — | — | — | ||||||
| Total | $902.56M | $1.11B | $1.31B |
Biomarin Pharmaceutical brought in $1.31B from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $2.84B it reports by product and service, so these revenue lines do not cover all of its revenue. Marketed By Company was the largest at $1.10B (84.1%), ahead of Marketed By Sanofi at $208.51M (15.9%).
Compared with fiscal 2024, Marketed By Company grew 19.5% to $1.10B and Marketed By Sanofi grew 13.4% to $208.51M.
United States was Biomarin Pharmaceutical’s largest region in fiscal 2018, bringing in $560.03M of $1.51B (37%).
| Geography | FY 2013 | FY 2015 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|---|
| United States | $444.08M | $411.88M | $588.24M | $560.03M | |
| Europe | $171.22M | $252.63M | $363.54M | $424.36M | |
| Rest Of World | $132.30M | $209.21M | $241.48M | $338.83M | |
| Latin America | $142.31M | $147.47M | $182.44M | $184.98M | |
| Total | $889.90M | $1.02B | $1.38B | $1.51B |
Biomarin Pharmaceutical brought in $1.51B from its four regions in fiscal 2018, the year ended December 31, 2018. That was up 9.6% from $1.38B in fiscal 2017. United States was the largest at $560.03M (37.1%), ahead of Europe at $424.36M (28.1%) and Rest Of World at $338.83M (22.5%). The remaining region, Latin America, brought in $184.98M.
Compared with fiscal 2017, Rest Of World grew fastest, up 40.3% to $338.83M, while United States fell the most, down 4.8% to $560.03M. From fiscal 2015 to 2018, combined revenue from these regions grew from $889.90M to $1.51B, a compound annual growth rate of 19.2%. United States' share of the total fell from 49.9% to 37.1%.
Biomarin Pharmaceutical (BMRN) reports its revenue by product and service, by contract with customer, sales channel and by geography. In fiscal 2025, Vimizim was its largest product and service line, bringing in $792.05M (27.9% of the total), followed by Products Excluding Aldurazyme at $544.47M (19.2%).
Vimizim was Biomarin Pharmaceutical's largest product and service line in fiscal 2025, bringing in $792.05M, or 27.9% of the $2.84B total across its nine product and service lines.
Marketed By Company was Biomarin Pharmaceutical's largest revenue line in fiscal 2025, bringing in $1.10B, or 84.1% of the $1.31B total across its two revenue lines.
United States was Biomarin Pharmaceutical's largest region in fiscal 2018, bringing in $560.03M, or 37.1% of the $1.51B total across its four regions.
Marketed By Company grew faster than Marketed By Sanofi in fiscal 2025, up 19.5% from $924.81M to $1.10B. Marketed By Sanofi grew 13.4% to $208.51M.
Every figure comes from Biomarin Pharmaceutical's annual financial filings, as reported. Each line keeps the name Biomarin Pharmaceutical gives it, and years follow its fiscal calendar.
Biomarin Pharmaceutical's revenue by product and service goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.